__NUXT_JSONP__("/drugs/Padeliporfin", (function(a,b){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:"padeliporfin di-potassium",conditionIndication:"Tookad is indicated as monotherapy for adult patients with previously untreated, unilateral, low risk, adenocarcinoma of the prostate with a life expectancy ≥ 10 years and:Clinical stage T1c or T2a;Gleason Score ≤ 6, based on high-resolution biopsy strategies;PSA ≤ 10 ng\u002FmL;3 positive cancer cores with a maximum cancer core length of 5 mm in any one core or 1-2 positive cancer cores with ≥ 50 % cancer involvement in any one core or a PSA density ≥ 0.15 ng\u002FmL\u002Fcm³.",inn:"padeliporfin",marketingAuthorisationDate:"2017-11-10 01:00:00",marketingAuthorisationHolder:"STEBA Biotech S.A",medicineName:"Tookad",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Ftookad"}],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"759457-82-4",chebiId:"",chemicalFormula:"C37H43N5O9S.Pd",definition:"A vascular-acting photosensitizer consisting of a water-soluble, palladium-substituted bacteriochlorophyll derivative with potential antineoplastic activity. Upon administration, paldeliporfin is activated locally when the tumor bed is exposed to low-power laser light; reactive oxygen species (ROS) are formed upon activation and ROS-mediated necrosis may occur at the site of interaction between the photosensitizer, light and oxygen. Vascular-targeted photodynamic therapy (VTP) with padeliporfin may allow tumor-site specific cytotoxicity while sparing adjacent normal tissues.",fdaUniiCode:"EEO29FZT86",identifier:"C78481",preferredName:a,semanticType:"Organic Chemical",subclassOf:["C1420"],synonyms:["PADELIPORFIN",a,"Palladium-Bacteriochlorophyll Derivative WST11","WST11"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FPadeliporfin",extension:".json",createdAt:b,updatedAt:b}}],fetch:{},mutations:void 0}}("Padeliporfin","2021-10-30T13:45:14.053Z")));